{"groups":[{"description":"10 mg/m2 by vein (IV) over 1 hour daily for 10 days","id":"FG000","title":"Decitabine 10 mg/m2 IV"},{"description":"20 mg/m2 IV over 1 hour daily for 5 days","id":"FG001","title":"Decitabine 20 mg/m2 IV"},{"description":"20 mg/m2 subcutaneous (SQ) daily for 5 days","id":"FG002","title":"Decitabine 20 mg/m2 SQ"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"93"},{"groupId":"FG002","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"93"},{"groupId":"FG002","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Enrollment of 128 patients: 1 patient withdrew consent prior to treatment; 3 did not meet eligibility requirement for a total of 124 evaluable patients.","recruitmentDetails":"Recruitment Period 6/4/03 - 5/18/09; all patients were registered at The University of Texas M.D. Anderson Cancer Center."}